Lymphoma Clinical Trials in Boston

Showing 101-120 of 544 trials

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

NCT05079282

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Relapsed or Refractory T Cell Lymphoma

Ono Pharmaceutical Co., Ltd.217 participantsStarted Dec 2021

Birmingham, Alabama, United States • Duarte, California, United States • Orange, California, United States +17 more locations

RECRUITINGNA< 1 mile

CONFIRM: Magnetic Resonance Guided Radiation Therapy

NCT04368702

This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

Gastric CancerInvasive Breast Cancerin Situ Breast Cancer+3 more

Brigham and Women's Hospital70 participantsStarted May 2021

Boston, Massachusetts, United States • Boston, Massachusetts, United States

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Lymphoma Trials in Other Cities

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Venetoclax Plus Inotuzumab for B-ALL

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Avo In R/R And Previously Untreated MCL

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Removing Transfusion Dependence as a Barrier to Hospice Enrollment

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Other Conditions in Boston